The French biotech company closed the trading session on Friday, October 17, at €78.50, down by 3.21% from the previous day's closing price of €81.10. This decline occurred in a generally pressured Parisian market, with the CAC 40 dropping 0.18% to 8,174.2 points, affected by concerns over American regional banks. Trading volumes remained modest, with only 0.1% of the capital traded, indicating investor caution after several sessions of gains. Over the past week, the stock has shown a slight negative performance of -0.63%, but this correction does not undermine the exceptional momentum of recent months. Since July, Abivax has seen a meteoric rise of 833.4% over three months and 816% over a year, largely driven by the positive Phase 3 results of its drug candidate obefazimod presented in early October.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technical analysis reveals an ambivalent market situation. The Relative Strength Index (RSI) stands at 72, indicating that the stock has been in an overbought zone for several sessions, which may explain the current pause. This configuration often suggests a consolidation phase following a rapid rise, with investors taking profits before a possible rebound. However, the stock remains comfortably positioned above its moving averages, at €69.99 for the MM50 and €25.37 for the MM200, confirming a fundamentally bullish trend. The Bollinger Bands, currently framing the stock's fluctuations between €64.95 and €84.25, show that the price is approaching the upper limit of its statistical range of movement. The MACD, with a main line at 3.02 and a signal line at 2.04, remains in positive territory with a histogram at 0.99, indicating generally favorable momentum despite the day's decline. The technical support threshold identified at €68.60 provides a safety margin of nearly 13% relative to the current price, while the resistance at €83.60 remains within reach.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
